Phase III clinical trial of SYS6043 developed by Shiyao Group (01093) for first-line treatment of recurrent or metastatic triple-negative breast cancer that cannot be surgically resected was officially launched in China

Zhitong Finance App News, Shiyao Group (01093) announced that the phase III clinical trial of SYS6043 developed by the group for first-line treatment of recurrent or metastatic triple-negative breast cancer that cannot be surgically resected has been officially launched at the first research center in China.

This product is an antibody-conjugated drug (ADC) that targets B7-H3 developed by the Group. The antibody part can specifically bind to the cell surface expressing B7-H3 and internalize it into the cell; its linker-drug (Linker-Drug) is a tetrapeptide ligand-conjugated topoisomerase I inhibitor, which can release small molecules of toxins to kill tumor cells through protease-specific cleavage, and exerts a bystander effect on non-specific killing surrounding tumor tissue cells. Unlike antibodies that use traditional wild-type crystallizable fragments (Fc), this product can reduce lymphocyte uptake and reduce the risk of off-target toxicity, thereby improving the safety of treatment.

The clinical trial launched this time is a randomized, open, multi-center phase III clinical trial. The purpose is to evaluate the clinical efficacy and safety of this product among participants who chose chemotherapy to treat recurrent or metastatic triple-negative breast cancer that cannot be surgically resected on the first line. Currently, the recruitment and screening of participants for this phase III clinical trial is being actively promoted.